ArticleJournal of health, population, and nutrition2025
Global burden of liver cirrhosis: trends from 1990-2021 and projections to 2060.
Article in Journal of health, population, and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Revisiting Anti-HCV Seropositivity: Signal Intensity, Diagnostic Uncertainty, and the Limitations of Fixed Cut-Offs.Diagnostics (Basel, Switzerland) · 2026Article
- With no lysine kinase 1 in hepatic stellate cells promotes mouse and human liver fibrosis through glycolytic triosephosphate isomerase 1.Hepatology (Baltimore, Md.) · 2026Article
- Article
- Direct-Acting Antivirals Are a Milestone for Hepatitis C Virus Infection? Analysis of 15 Years of Patient and Diagnosis Data from a Region in Türkiye.Journal of clinical medicine · 2026Article
- Spatiotemporal lag effects of surface water quality on liver cirrhosis mortality risk in China: a nine-year time-series study of environmental driving mechanism.BMC public health · 2026Article
- LGALS3 marks a pro-inflammatory, efferocytosis-low hepatic macrophage state and promotes hepatic stellate cell activation through the candidate receptor ANXA2 in liver cirrhosis.Frontiers in immunology · 2026Article
- Opioid type, rather than liver function, is associated with postoperative nausea and vomiting after painless gastroscopy in decompensated cirrhosis.Frontiers in pharmacology · 2026Article
- Endoplasmic Reticulum-Targeting Natural Compounds: A Novel Frontier in Alleviating Liver Fibrosis.Drug design, development and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLiver cirrhosis, a progressive and debilitating condition characterized by extensive fibrosis and disruption of hepatic architecture, remains a significant global health challenge, primarily arising from chronic hepatitis and other liver diseases.
methodsData from the 2021 Global Burden of Disease (GBD) database were utilized to analyze trends in the incidence, deaths, disability-adjusted life years (DALYs), and prevalence of liver cirrhosis from 1990 to 2021 across various geographic regions, aiming to provide guidance for future disease burden interventions. The Bayesian age-period-cohort (BAPC) model was utilized for predicting trends up to 2060.
resultsIn 2021, the global incidence of liver cirrhosis was recorded at 58,417,006 cases. Total death cases attributed to liver cirrhosis escalated to 1,425,142 in 2021, although the age-standardized death rate (ASDR) demonstrated a marked decline. Regional disparities were evident, with the highest incidence reported in North Africa and the Middle East, particularly in low Socio-Demographic Index (SDI) regions that bear a disproportionate burden. Following the current trends, it is projected that by 2060, the ASDR, ASPR, and DALYs rate for liver cirrhosis will progressively decline.
conclusionsThe findings underscore the need for enhanced strategies to combat liver cirrhosis, especially in high-burden regions. Specifically, the global incidence of liver cirrhosis has increased by 58.21% from 1990 to 2021. This prediction to 2060 holds strategic significance for guiding the adjustment of priorities in future disease burden management efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.